Review
Biochemistry & Molecular Biology
David Aluja, Sara Delgado-Tomas, Marisol Ruiz-Meana, Jose A. Barrabes, Javier Inserte
Summary: Despite advances in treatment, heart failure remains a major cause of illness and death. Preventing myocardial hypertrophy, which is an independent risk factor for heart failure, is a clinical objective. Recent studies suggest that calpains, a type of protein, play a role in the development of cardiac hypertrophy, and inhibiting calpains may be a potential pharmacological strategy. New compounds are being developed and tested in animal models to evaluate the effectiveness of calpain inhibition in treating pathological cardiac hypertrophy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Gaku Tsuji, Kazuhiko Yamamura, Koji Kawamura, Makiko Kido-Nakahara, Takamichi Ito, Takeshi Nakahara
Summary: Atopic dermatitis (AD) is a chronic inflammatory skin disease with a complex pathogenesis involving skin barrier dysfunction, type II immune response, and pruritus. Advances in understanding the immunological mechanisms of AD have identified multiple novel therapeutic targets. New biologic agents targeting various cytokines and pathways are being developed for systemic and topical therapy, including JAK inhibitors, histamine H4 receptor antagonists, and microbiome modulation. This review provides insights into the current and future directions of novel therapies for AD and highlights their mechanisms of action and efficacy, supporting the advancement of precision medicine in the treatment of AD.
Review
Cardiac & Cardiovascular Systems
Christelle Lteif, Ali Ataya, Julio D. Duarte
Summary: PH caused by LHD is believed to be the most common form, with challenges in treatment. Specific therapies for PH-LHD have not been identified yet, and pulmonary artery hypertension-targeted therapies are not recommended.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2021)
Review
Endocrinology & Metabolism
Misganaw Asmamaw Mengstie, Endeshaw Chekol Abebe, Awgichew Behaile Teklemariam, Anemut Tilahun Mulu, Assefa Agegnehu Teshome, Edgeit Abebe Zewde, Zelalem Tilahun Muche, Muluken Teshome Azezew
Summary: Diabetes Mellitus is a global health issue that can lead to various complications, including cardiovascular diseases such as heart failure. While hypertension and coronary artery disease are commonly associated with heart failure in diabetes patients, it is also prevalent even in the absence of these risk factors. Understanding the cellular and molecular mechanisms by which diabetes increases the risk of heart failure is crucial for developing effective therapeutics to prevent these changes.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Pharmacology & Pharmacy
Alexander J. Winkle, Drew M. Nassal, Rebecca Shaheen, Evelyn Thomas, Shivangi Mohta, Daniel Gratz, Seth H. Weinberg, Thomas J. Hund
Summary: Cardiac hypertrophy is associated with adverse outcomes in cardiovascular diseases. The link between pathophysiological stress stimuli and specific myocyte/heart growth profiles remains unclear. This review discusses the molecular mechanisms underlying cardiac hypertrophy and highlights the role of spectrin-based cytoskeleton in regulating myocyte dimensions. Opportunities for directing myocyte growth in response to hypertrophic stimuli as a therapeutic approach are also discussed.
EXPERT OPINION ON THERAPEUTIC TARGETS
(2022)
Article
Cardiac & Cardiovascular Systems
Albert Henry, Maria Gordillo-Maranon, Chris Finan, Amand F. Schmidt, Joao Pedro Ferreira, Ravi Karra, Johan Sundstrom, Lars Lind, Johan Arnlov, Faiez Zannad, Anders Malarstig, Aroon D. Hingorani, R. Thomas Lumbers
Summary: This study investigated the associations and causal relationships of 90 cardiovascular proteins with heart failure (HF). It identified 44 proteins that were associated with incident HF, of which 8 showed evidence of a causal relationship and 7 were druggable. Adrenomedullin (ADM) was highlighted as a particularly promising drug target.
Review
Biochemistry & Molecular Biology
Lindsay Kraus, Brianna Beavens
Summary: Cardiovascular diseases are a leading global cause of death, lacking a cure. Epigenetics and chromatin remodeling have emerged as promising interventions. Recent advancements in bioinformatics and gene therapy have particularly advanced the field of chromatin remodeling, specifically for the treatment of heart failure. Understanding changes to chromatin architecture has revealed potential methods for altering the progression of cardiac diseases through genomic sequencing, targeting cardiac genes, utilizing RNA molecules, and employing chromatin remodeler complexes. This understanding may lead to individualized pharmaceutical interventions and biomarkers for major disease states, ultimately paving the way for future therapeutic approaches.
Review
Biochemistry & Molecular Biology
Areeba Nisar, Zubair Ahmed, Hsiangkuo Yuan
Summary: Migraine is a debilitating neurological condition that affects many patients' quality of life. Despite the success of new therapies, not all patients benefit significantly. Understanding the mechanisms involved in migraine can lead to the discovery of novel therapeutic targets for improved treatment options.
Review
Medicine, General & Internal
Teruhiko Imamura, Nikhil Narang, Koichiro Kinugawa
Summary: New therapeutics have significantly reduced clinical risk for patients with chronic heart failure. Adaptive servo-ventilation is a novel treatment option for patients refractory to conventional therapies. Patients who do not respond to oral medical therapy alone may benefit from these new treatment strategies.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Pharmacology & Pharmacy
Anna Goracy, Jakub Rosik, Joanna Szostak, Bartosz Szostak, Szymon Retfinski, Filip Machaj, Andrzej Pawlik
Summary: Heart failure is a complex clinical syndrome caused by the unsuccessful compensation of symptoms of myocardial damage. Mitochondrial dysfunction is a process that occurs due to the disruption of metabolic and energetic pathways in the myocardium. This review focuses on new therapeutic strategies targeting mitochondrial function in the treatment of heart failure.
EXPERT OPINION ON THERAPEUTIC TARGETS
(2023)
Review
Medicine, Research & Experimental
Xiaoguang Wu, Yi Li, Shuchen Zhang, Xiang Zhou
Summary: Cell death is a significant factor in cardiovascular disease pathophysiology. Ferroptosis, a regulated cell death form characterized by iron overload and lipid hydroperoxide accumulation, is closely associated with various diseases and plays critical roles in cardiomyopathy, myocardial infarction, ischemia/reperfusion injury, and heart failure. Targeting ferroptosis may offer potential novel therapeutic strategies for cardiovascular diseases.
Review
Cardiac & Cardiovascular Systems
Maneesha Sharma, Lokesh Kumar Bhatt
Summary: This review discusses emerging targets for the treatment of heart failure.
CURRENT CARDIOLOGY REPORTS
(2022)
Review
Physiology
Marta Reina-Couto, Patricia Pereira-Terra, Janete Quelhas-Santos, Carolina Silva-Pereira, Antonio Albino-Teixeira, Teresa Sousa
Summary: Inflammation is a major contributor to different types of heart failure, but trials of anti-inflammatory strategies in HF patients have shown inconsistent results. Future therapeutic advances may involve tailored anti-inflammatory treatments based on individual inflammatory profiles and the development of resolution pharmacology targeting inflammation pathways in HF.
FRONTIERS IN PHYSIOLOGY
(2021)
Review
Cell Biology
Changhai Tian, Jessica N. Ziegler, Irving H. Zucker
Summary: Extracellular vesicles (EVs) are important in cardiovascular diseases (CVDs), particularly in heart failure, where they transfer bioactive substances. miRNAs in EVs play a role in the progression of heart failure and their sorting is tightly controlled. Extracellular miRNAs, especially circulating EV-miRNAs, show promise as biomarkers and therapeutic targets for heart failure. This review summarizes the latest progress in understanding the role of EV-miRNAs in heart failure and their potential in therapeutic strategies.
Article
Medicine, Research & Experimental
Bernhard Laggerbauer, Stefan Engelhardt
Summary: The discovery of microRNAs and their role in cardiovascular diseases has sparked interest in using microRNAs as drug targets. MicroRNA-based drugs have made significant progress in preclinical and clinical testing for cardiovascular diseases, showing great potential in treatment.
JOURNAL OF CLINICAL INVESTIGATION
(2022)
Review
Cardiac & Cardiovascular Systems
R. Ferrari, M. Bertini, C. Blomstrom-Lundqvist, D. Dobrev, P. Kirchhof, C. Pappone, U. Ravens, J. Tamargo, L. Tavazzi, G. G. Vicedomini
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2016)
Article
Cardiac & Cardiovascular Systems
Susana Canon, Ricardo Caballero, Adela Herraiz-Martinez, Marta Perez-Hernandez, Begona Lopez, Felipe Atienza, Jose Jalife, Leif Hove-Madsen, Eva Delpon, Antonio Bernad
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
(2016)
Article
Multidisciplinary Sciences
Jose Rivera-Torres, Conrado J. Calvo, Anna Llach, Gabriela Guzman-Martinez, Ricardo Caballero, Cristina Gonzalez-Gomez, Luis J. Jimenez-Borreguero, Juan A. Guadix, Fernando G. Osorio, Carlos Lopez-Otin, Adela Herraiz-Martinezd, Nuria Cabello, Alex Vallmitjana, Raul Benitez, Leslie B. Gordon, Jose Jalife, Jose M. Perez-Pomares, Juan Tamargo, Eva Delpon, Leif Hove-Madsen, David Filgueiras-Rama, Vicente Andres
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2016)
Editorial Material
Cardiac & Cardiovascular Systems
Giuseppe Ambrosio, Michel Komajda, Alessandro Mugelli, Jose Lopez-Sendon, Juan Tamargo, John Camm
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2016)
Article
Multidisciplinary Sciences
Ricardo Caballero, Raquel G. Utrilla, Irene Amoros, Marcos Matamoros, Marta Perez-Hernandez, David Tinaquero, Silvia Alfayate, Paloma Nieto-Marin, Guadalupe Guerrero-Serna, Qing-hua Liu, Roberto Ramos-Mondragon, Daniela Ponce-Balbuena, Todd Herron, Katherine F. Campbell, David Filgueiras-Rama, Rafael Peinado, Jose L. Lopez-Sendon, Jose Jalife, Eva Delpon, Juan Tamargo
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2017)
Review
Cardiac & Cardiovascular Systems
Seif El Hadidi, Giuseppe Rosano, Juan Tamargo, Stefan Agewall, Heinz Drexel, Juan Carlos Kaski, Alexander Niessner, Basil S. Lewis, Andrew J. S. Coats, Gianluigi Savarese
Summary: Heart failure is a chronic and potentially life-threatening condition. To improve clinical outcomes and avoid inappropriate drug prescriptions, a comprehensive prescribing review tool is compiled based on the latest guidelines, scientific evidence, and expert opinions.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
(2022)
Review
Cardiac & Cardiovascular Systems
Emma Forton Magavern, Juan Carlos Kaski, Richard M. Turner, Heinz Drexel, Azara Janmohamed, Andrew Scourfield, Daniel Burrage, Christopher N. Floyd, Elizabeth Adeyeye, Juan Tamargo, Basil S. Lewis, Keld Per Kjeldsen, Alexander Niessner, Sven Wassmann, Patrick Sulzgruber, Pascal Borry, Stefan Agewall, Anne Grete Semb, Gianluigi Savarese, Munir Pirmohamed, Mark J. Caulfield
Summary: There is a growing body of evidence supporting the use of pharmacogenomics in cardiovascular pharmacology, but international cardiovascular societies lack a common position on the diverse availability, interpretation, and application of such data, as well as the challenges presented by variations in clinical practice across European countries. In addition to barriers to implementing pharmacogenomic testing and complexity in acting on results, there are disparities in the availability of resources and expertise internationally within Europe. Legal and ethical considerations for genomic testing and clinical therapeutic application also require serious thought.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
(2022)
Editorial Material
Cardiac & Cardiovascular Systems
Jose Luis Merino, Juan Tamargo
CARDIOVASCULAR DRUGS AND THERAPY
(2021)
Editorial Material
Cardiac & Cardiovascular Systems
Juan Tamargo, Stefan Agewall
Summary: This study investigates the association between oral fluoroquinolones and the risk of aortic or mitral regurgitation, suggesting a potential link between these drugs and valvular heart disease.
EUROPEAN HEART JOURNAL
(2021)
Article
Cardiac & Cardiovascular Systems
Jose Lopez-Sendon, Raul Moreno, Juan Tamargo
Summary: The treatment of ischemic heart disease involves three pillars: a healthy lifestyle, myocardial revascularisation, and medical therapy. The ISCHEMIA trial compared an early invasive strategy with revascularisation plus optimal medical therapy against initial optimal medical therapy alone with revascularisation reserved for inadequate symptom control. The study included over 5,000 patients with stable coronary artery disease and moderate to severe myocardial ischemia, and found no significant differences in relevant clinical outcomes over a follow-up of 3.2 years.
EUROPEAN CARDIOLOGY REVIEW
(2021)
Review
Cardiac & Cardiovascular Systems
Juan Tamargo, Jose Lopez-Sendon
Summary: The advances in the diagnosis and treatment of coronary artery diseases have greatly reduced mortality rates and extended life expectancy. It is important for patients to adopt a healthy lifestyle, control risk factors, and take medications to prevent heart attacks. Tailored therapy for angina, the most common symptom of chronic coronary artery disease, involves selecting antianginal drugs based on the individual patient's profile.
Editorial Material
Cardiac & Cardiovascular Systems
Juan Tamargo, Koji Hasegawa, Stefan Agewall
EUROPEAN HEART JOURNAL
(2022)
Review
Cardiac & Cardiovascular Systems
Juan Tamargo, Juan Carlos Kaski, Takeshi Kimura, Jack Charles Barton, Ko Yamamoto, Maki Komiyama, Heinz Drexel, Basil S. Lewis, Stefan Agewall, Koji Hasegawa
Summary: Awareness of racial/ethnic disparities in cardiovascular disease is crucial for providing effective healthcare. Differences in prevalence, risk factors, and drug response among different ethnic groups are mainly related to genetic variations. Understanding these differences helps optimize treatment and improve outcomes.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
(2022)
Review
Cardiac & Cardiovascular Systems
Juan Tamargo, Stefan Agewall, Claudio Borghi, Claudio Ceconi, Elisabetta Cerbai, Gheorghe A. Dan, Peter Ferdinandy, Erik Lerkevang Grove, Bianca Rocca, Patrick Sulzgruber, Anne Grete Semb, Samuel Sossalla, Alexander Niessner, Juan Carlos Kaski, Dobromir Dobrev
Summary: Cardiovascular diseases (CVD) are the leading cause of death globally, and current pharmacotherapy is not optimal. Therefore, there is an urgent need to develop new drugs with higher efficacy and better safety profiles. This review summarizes the recent advances in cardiovascular pharmacology in 2022, including the approval of first-in-class drugs for the treatment of obstructive hypertrophic cardiomyopathy, type 2 diabetes mellitus, and heart failure independent of left ventricular ejection fraction. It also discusses the repurposing of existing drugs and the potential of new therapies for the treatment of various cardiovascular diseases.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
(2023)
Review
Cardiac & Cardiovascular Systems
Faiez Zannad, Wendy Gattis Stough, Raymond J. Lipicky, Juan Tamargo, George L. Bakris, Jeffrey S. Borer, Maria de los Angeles Alonso Garcia, Samy Hadjadj, Wolfgang Koenig, Stuart Kupfer, Peter A. McCullough, Ofri Mosenzon, Stuart Pocock, Andre J. Scheen, Harald Sourij, Bart Van der Schueren, Christina Stahre, William B. White, Gonzalo Calvo
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
(2016)
